Biosimilars are authorized for the same, or fewer, indications than those treated with the corresponding original biologics. Today there are biosimilars in key therapeutic areas as cancer, diabetes, rheumatoid arthritis, inflammatory intestinal and dermatological diseases as well as in fertility treatments.

It is precisely these areas that will continue to be most affected by the biologics patent expiration in the coming years and therefore will create a window of opportunity for the development and launch of new biosimilars. As an example, it should be noted that insulins alone account for 15.900 million dollars in the market and Anti-TNF drugs, 15.800 million dollars (IMS Health).

In the case of Spain, 64% of biotech drug patents will expire in the next five years, which could mean potential savings due to the entry of biosimilars from 450 million euros in 2017.

Therefore, from this blog we want to inform and train about biosimilar medicines, both already approved by the EMA such as those that are under development and in the not too distant future, they will be prescribed in new therapeutic areas not previously covered.